GlaxoSmithKline PLC's chief executive said the British drug giant was open to spinning off its consumer health-care business at some point in the future, according to comments in a Financial Times interview published Sunday. Glaxo CEO Andrew Witty said there were no immediate plans for such a break-up, however, and voiced optimistism about turning the company around, citing a $20 billion consumer-health-care joint venture with Novartis AG , the FT reported. Glaxo is currently struggling with a variety of challenges, including a bribery scandal in China, and last week the pharmaceutical major issued a profit warning.

Copyright © 2014 MarketWatch, Inc.